Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -5.7M | 19.5% |
| Cost of Revenue | 5.7M | 19.5% |
| Operating expense | 22M | 6.1% |
| Net Income | -20M | 5.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 164M | 8.8% |
| Total Liabilities | 30M | 2.7% |
| Total Equity | 134M | 11% |
| Shares Outstanding | 7.3M | 90% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -17M | 2.7% |
| Cash from investing | 24M | 97% |
EPS
Financial Highlights for Kezar Life Sciences in Q3 '24
Gross Profit stood at -5.7M, marking a 19.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 5.7M, a -19.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 22M, showing a -6.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -20M, showing a 5.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
